JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB263118

Human C11orf58 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

SMAP KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.
1 Images
Sanger Sequencing - Human C11orf58 knockout HeLa cell lysate (AB263118)
  • Sanger seq

Unknown

Sanger Sequencing - Human C11orf58 knockout HeLa cell lysate (AB263118)

Homozygous : 1 bp deletion in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab263118-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human C11orf58 knockout HeLa cell lysate", "number":"AB263118-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB263118-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
SMAP
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SMAP (Small Arf-GTPase Activating Proteins) plays a role in the regulation of Arf GTPases and exhibits GTPase-activating protein (GAP) activity. SMAP also known as SMAP1 and SMAP2 is associated with endocytic and membrane traffic processes. The two main isoforms SMAP1 and SMAP2 have molecular masses of approximately 100 kDa and are expressed mainly in the cytoplasm of various cell types including those in the brain liver and kidney.
Biological function summary

SMAP influences cellular processes by modulating membrane trafficking dynamics. SMAP operates as part of a complex involved in the regulation of vesicular transport. By assisting the hydrolysis of GTP bound to Arf proteins SMAP can control vesicle budding and transport at the Golgi apparatus. This function enables SMAP to participate actively in managing intracellular transport and membrane curvature events impacting cell signaling and other cellular activities.

Pathways

SMAP functions in the clathrin-mediated endocytosis pathway and the Golgi transport pathway. Through its activity SMAP links to the Arf family proteins which are components in these pathways. In clathrin-mediated endocytosis SMAP facilitates cargo selection and vesicle formation interacting with molecules like AP-2. SMAP's GAP activity is important in Golgi-associated vesicular trafficking where it regulates the cycle of Arf GTPases contributing to vesicle docking and fusion events.

Abnormalities in SMAP function can influence conditions such as cancer and neurodegenerative diseases. Alterations affecting SMAP expression or activity may lead to disrupted membrane trafficking and defective signal transduction pathways that are related to cancer metastasis. Additionally connections with Arf proteins link SMAP to neurological diseases due to impaired synaptic vesicle cycling and transport highlighting its significance in maintaining cellular homeostasis in neural tissues.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com